CL2023002555A1 - Compuestos macrocíclicos y métodos de uso de los mismos (divisional ). - Google Patents

Compuestos macrocíclicos y métodos de uso de los mismos (divisional ).

Info

Publication number
CL2023002555A1
CL2023002555A1 CL2023002555A CL2023002555A CL2023002555A1 CL 2023002555 A1 CL2023002555 A1 CL 2023002555A1 CL 2023002555 A CL2023002555 A CL 2023002555A CL 2023002555 A CL2023002555 A CL 2023002555A CL 2023002555 A1 CL2023002555 A1 CL 2023002555A1
Authority
CL
Chile
Prior art keywords
methods
macrocyclic
eulbm
binding motif
divisional
Prior art date
Application number
CL2023002555A
Other languages
English (en)
Inventor
Fuhrmann Jakob
Fairbrother Wayne
Wu Hao
Murray Jeremy
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of CL2023002555A1 publication Critical patent/CL2023002555A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/52—Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proveen compuestos macrocíclicos que comprenden un motivo de unión a la ubiquitina ligasa E3 (EULBM) y al menos un aminoácido, y métodos para preparar y usar tales EULBM macrocíclicos para el tratamiento del cáncer o de una condición fibrótica. También se proveen inductores químicos heterobifuncionales macrocíclicos de degradación (CIDE) que comprenden un motivo de unión a la ubiquitina ligasa E3 (EULBM) y un motivo de unión a la proteína diana (TPBM) unidos por al menos un aminoácido.
CL2023002555A 2020-06-23 2023-08-29 Compuestos macrocíclicos y métodos de uso de los mismos (divisional ). CL2023002555A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063043071P 2020-06-23 2020-06-23

Publications (1)

Publication Number Publication Date
CL2023002555A1 true CL2023002555A1 (es) 2024-01-26

Family

ID=77207221

Family Applications (4)

Application Number Title Priority Date Filing Date
CL2022003643A CL2022003643A1 (es) 2020-06-23 2022-12-19 Compuestos macrocíclicos y métodos de uso de los mismos.
CL2023002555A CL2023002555A1 (es) 2020-06-23 2023-08-29 Compuestos macrocíclicos y métodos de uso de los mismos (divisional ).
CL2025000750A CL2025000750A1 (es) 2020-06-23 2025-03-13 Compuestos macrocíclicos y métodos de uso de los mismos.
CL2025000748A CL2025000748A1 (es) 2020-06-23 2025-03-13 Compuestos macrocíclicos y métodos de uso de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2022003643A CL2022003643A1 (es) 2020-06-23 2022-12-19 Compuestos macrocíclicos y métodos de uso de los mismos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
CL2025000750A CL2025000750A1 (es) 2020-06-23 2025-03-13 Compuestos macrocíclicos y métodos de uso de los mismos.
CL2025000748A CL2025000748A1 (es) 2020-06-23 2025-03-13 Compuestos macrocíclicos y métodos de uso de los mismos.

Country Status (17)

Country Link
US (2) US12187816B2 (es)
EP (1) EP4168121A2 (es)
JP (1) JP2023532233A (es)
KR (1) KR20230026461A (es)
CN (1) CN115702026A (es)
AR (1) AR122707A1 (es)
AU (1) AU2021297799A1 (es)
BR (1) BR112022026364A2 (es)
CA (1) CA3185149A1 (es)
CL (4) CL2022003643A1 (es)
CO (1) CO2022018532A2 (es)
CR (1) CR20220658A (es)
IL (1) IL299163A (es)
MX (1) MX2022016454A (es)
PE (1) PE20230617A1 (es)
TW (1) TWI906316B (es)
WO (1) WO2021262731A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260001914A1 (en) * 2022-07-21 2026-01-01 Merck Sharp & Dohme Llc Macrocyclic peptides targeting kras
ES3041442T3 (en) * 2022-12-27 2025-11-12 Evonik Oxeno Gmbh & Co Kg Process for the preparation of a phosphoramidite and its further conversion to monophosphite
KR20260028831A (ko) * 2023-06-26 2026-03-04 알부넥스트 엘엘씨 Glp-1/gip/글루카곤 수용체를 활성화시키는 알부민 결합 거대분자 삼중효능제 및 이를 위한 방법

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4144233A (en) 1977-02-16 1979-03-13 The Dow Chemical Company Method for preparing benzo-(1,3,4)-benzotriazepines
US5185331A (en) 1991-05-14 1993-02-09 Merck & Co., Inc. Triazolobenzodiazepines
ES2233070T3 (es) * 1998-08-20 2005-06-01 ELI LILLY & COMPANY Sintesis de analogos peptidicos ciclicos modificados en el anillo.
WO2006129623A1 (ja) 2005-05-30 2006-12-07 Mitsubishi Tanabe Pharma Corporation チエノトリアゾロジアゼピン化合物及びその医薬としての用途
KR101600634B1 (ko) 2007-12-28 2016-03-07 미쓰비시 타나베 파마 코퍼레이션 항암제
EP3050885B1 (en) 2009-11-05 2017-10-18 GlaxoSmithKline LLC Benzodiazepine bromodomain inhibitor
AU2010314395B2 (en) 2009-11-05 2015-04-09 Glaxosmithkline Llc Benzodiazepine bromodomain inhibitor
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CN103119160B (zh) 2010-05-14 2016-06-01 达那-法伯癌症研究所 用于调节代谢的组合物和方法
PL2902030T3 (pl) 2010-05-14 2017-07-31 Dana-Farber Cancer Institute, Inc. Związki tienotriazolodiazepinowe do leczenia nowotworu
JP5844358B2 (ja) 2010-06-22 2016-01-13 グラクソスミスクライン エルエルシー ベンゾトリアゾロジアゼピン化合物を含むブロモドメイン阻害剤
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
WO2013106646A2 (en) 2012-01-12 2013-07-18 Yale University Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
JP6532599B2 (ja) 2015-09-02 2019-06-19 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ ブロモドメイン阻害薬としての使用のためのピリジノンジカルボキサミド
EP3675878A4 (en) * 2017-10-02 2021-06-16 Fred Hutchinson Cancer Research Center LUTEINIZING HORMONE RECEPTOR BINDERS AND LUTEINIZING HORMONAGONISTS FOR IDENTIFICATION, EXPANSION, ABLATION AND MODIFICATION OF PRIMITIVE STEM CELL POPULATIONS
EP3724216A1 (en) 2017-12-15 2020-10-21 Dana Farber Cancer Institute, Inc. Stabilized peptide-mediated targeted protein degradation
WO2019162974A1 (en) * 2018-02-23 2019-08-29 Ulisse Biomed S.R.L. Method to diagnose cancer progression based on prokaryotic biomarkers and molecules for use in the treatment of cancer progression

Also Published As

Publication number Publication date
TW202219056A (zh) 2022-05-16
CL2025000750A1 (es) 2025-07-04
MX2022016454A (es) 2023-03-06
CO2022018532A2 (es) 2022-12-30
IL299163A (en) 2023-02-01
US12187816B2 (en) 2025-01-07
AU2021297799A1 (en) 2022-12-22
CL2022003643A1 (es) 2023-05-26
WO2021262731A3 (en) 2022-02-24
AR122707A1 (es) 2022-09-28
CN115702026A (zh) 2023-02-14
JP2023532233A (ja) 2023-07-27
KR20230026461A (ko) 2023-02-24
EP4168121A2 (en) 2023-04-26
CA3185149A1 (en) 2021-12-30
BR112022026364A2 (pt) 2023-01-17
US20250129125A1 (en) 2025-04-24
WO2021262731A2 (en) 2021-12-30
CL2025000748A1 (es) 2025-07-04
US20220106361A1 (en) 2022-04-07
TWI906316B (zh) 2025-12-01
CR20220658A (es) 2023-04-26
PE20230617A1 (es) 2023-04-14

Similar Documents

Publication Publication Date Title
CL2023002555A1 (es) Compuestos macrocíclicos y métodos de uso de los mismos (divisional ).
BR112021017583A2 (pt) Compostos, composições e métodos para o tratamento de doença
MX2024014691A (es) Enlazadores de conjugacion mejorados
BR112021020285A2 (pt) Métodos e composições para degradação de proteína alvejada
MX2024002261A (es) Molecula de union de fap/cd40 y uso medicinal de la misma.
PY2263012A (es) Composiciones para el control fúngico y métodos relacionados
MX2024002411A (es) Antagonista biológico que contiene anillos aromáticos, y método para su preparación y su uso.
ECSP23019525A (es) Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos
MX2024003439A (es) Métodos para tratar tumores sólidos usando compuestos de éter macrocíclico heteroaromático.
BR112022012278A2 (pt) Combinações
CO2021012375A2 (es) Inhibidor de la interacción proteína-proteína wdr5 basado en anilina, método para preparar el mismo y uso del mismo
MX2022007623A (es) Combinaciones.
WO2024077023A3 (en) Cereblon-recruiting bcl-xl/bcl-2 dual degraders
CO2021001277A2 (es) Inhibidores de triazol glicolato oxidasa
MX2022007626A (es) Combinaciones.
MX2021014226A (es) Arn terapeutico para cancer de ovario.
DOP2024000085A (es) Compuestos dirigidos a pmp22 para el tratamiento de la enfermedad de charcot-marie-tooth
AR128704A1 (es) Procedimiento para preparar 4-metil-2-propan-2-il-piridin-3-carbonitrilo
DOP2025000055A (es) Moduladores de la alfa-1 antitripsina
EA202092540A1 (ru) Комбинации для лечения рака
ES2481450T3 (es) Proteasas específicas de ubiquitina responsables de la estabilidad de mcl 1 y su utilización
WO2021084441A3 (en) Methods and compositions for treatment of cancer
CL2024003050A1 (es) Método e intermediario para la preparación de apalutamida.
CL2023002558A1 (es) Uso de luvadaxistat para el tratamiento de deterioro cognitivo
DOP2022000083A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias